Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Fibroblast growth factor receptor type 4 as a potential therapeutic target in clear cell renal cell carcinoma

Fig. 4

Selective pharmacological inhibition of FGFR4 by BLU9931. A, Western blot analysis of intracellular signalling pathways Akt/mTOR, ERK1/2, and STAT3 3 h after BLU9931 treatment. The phosphorylation level transition of each signal pathway is shown according to the concentration gradient of BLU9931. B, MTS assay 72 h after BLU9931 treatment in ccRCC cell lines (A498, A704, 769-P), a non-ccRCC cell line (ACHN), and a normal renal cortical cell line (HRCEpC). ccRCC cell growth suppression was observed via the concentration gradient of BLU9931 at a lower level compared to HRCEpC cell suppression. Abbreviations: FGFR4, fibroblast growth factor receptor 4; RCC, renal cell carcinoma; mTOR, mammalian target of rapamycin; ERK, extracellular signal-regulated protein kinase; STAT, signal transducer and activator of transcription

Back to article page